Prelude Therapeutics Statistics
Share Statistics
Prelude Therapeutics has 55.04M shares outstanding. The number of shares has increased by 31.07% in one year.
| Shares Outstanding | 55.04M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.17% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 28.54M |
| Failed to Deliver (FTD) Shares | 512 |
| FTD / Avg. Volume | 0.14% |
Short Selling Information
The latest short interest is 2.94M, so 5.35% of the outstanding shares have been sold short.
| Short Interest | 2.94M |
| Short % of Shares Out | 5.35% |
| Short % of Float | 10.09% |
| Short Ratio (days to cover) | 9.84 |
Valuation Ratios
The PE ratio is -2.12 and the forward PE ratio is -0.76.
| PE Ratio | -2.12 |
| Forward PE | -0.76 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.09 |
| P/FCF Ratio | -2.33 |
| PEG Ratio | n/a |
Enterprise Valuation
Prelude Therapeutics has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 10.79, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.79 |
| Quick Ratio | 10.79 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.62 |
| Cash Flow / Debt | -72.29 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.51% and return on capital (ROIC) is -52.08%.
| Return on Equity (ROE) | -0.51% |
| Return on Assets (ROA) | -0.44% |
| Return on Capital (ROIC) | -52.08% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -951.81K |
| Employee Count | 128 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -81.61% in the last 52 weeks. The beta is 1.55, so Prelude Therapeutics's price volatility has been higher than the market average.
| Beta | 1.55 |
| 52-Week Price Change | -81.61% |
| 50-Day Moving Average | 1.33 |
| 200-Day Moving Average | 3.58 |
| Relative Strength Index (RSI) | 25.78 |
| Average Volume (20 Days) | 364.43K |
Income Statement
In the last 12 months, Prelude Therapeutics had revenue of $0 and earned -$121.83M in profits. Earnings per share was $-2.02.
| Revenue | 0 |
| Gross Profit | -1.17M |
| Operating Income | -132.28M |
| Net Income | -121.83M |
| EBITDA | -131.11M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.02 |
Balance Sheet
The company has $25.29M in cash and $16.89M in debt, giving a net cash position of $8.40M.
| Cash & Cash Equivalents | 25.29M |
| Total Debt | 16.89M |
| Net Cash | 8.40M |
| Retained Earnings | -456.39M |
| Total Assets | 197.22M |
| Working Capital | 134.16M |
Cash Flow
In the last 12 months, operating cash flow was -$107.06M and capital expenditures -$3.51M, giving a free cash flow of -$110.58M.
| Operating Cash Flow | -107.06M |
| Capital Expenditures | -3.51M |
| Free Cash Flow | -110.58M |
| FCF Per Share | -1.83 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
PRLD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -252.5% |
| FCF Yield | -250.52% |
Analyst Forecast
The average price target for PRLD is $4, which is 400% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 400% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -4.71 |
| Piotroski F-Score | 3 |